EirGenix Strikes Second Breast Cancer Biosimilar Deal with Sandoz, Total Signing and Milestone Payments Reach US$152 Million

EirGenix announced on November 12 that it has entered a global exclusive licensing and sales agreement with international biosimilar giant Sandoz AG for its HER2-positive breast cancer biosimilar EG1206A (Pertuzumab Biosimilar to Roche Perjeta), following their previous collaboration on the breast cancer biosimilar EG12014. Under the agreement, EirGenix is set to receive a total of US$152 million in upfront signing and milestone payments, with additional sales incentives based on market performance and a share of sales revenue once the product is commercialized.